169 related articles for article (PubMed ID: 20173089)
1. In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone.
Tong Z; Chandrasekaran A; Li H; Rotshteyn Y; Erve JC; Demaio W; Talaat R; Hultin T; Scatina J
Drug Metab Dispos; 2010 May; 38(5):801-7. PubMed ID: 20173089
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans.
Chandrasekaran A; Tong Z; Li H; Erve JC; DeMaio W; Goljer I; McConnell O; Rotshteyn Y; Hultin T; Talaat R; Scatina J
Drug Metab Dispos; 2010 Apr; 38(4):606-16. PubMed ID: 20053817
[TBL] [Abstract][Full Text] [Related]
3. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol.
Breyer-Pfaff U; Nill K
J Pharm Pharmacol; 2004 Dec; 56(12):1601-6. PubMed ID: 15563768
[TBL] [Abstract][Full Text] [Related]
4. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily.
Steckelbroeck S; Oyesanmi B; Jin Y; Lee SH; Kloosterboer HJ; Penning TM
J Pharmacol Exp Ther; 2006 Mar; 316(3):1300-9. PubMed ID: 16339391
[TBL] [Abstract][Full Text] [Related]
5. Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol.
Atalla A; Breyer-Pfaff U; Maser E
Xenobiotica; 2000 Aug; 30(8):755-69. PubMed ID: 11037109
[TBL] [Abstract][Full Text] [Related]
6. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.
Porter SJ; Somogyi AA; White JM
Br J Clin Pharmacol; 2000 Nov; 50(5):465-71. PubMed ID: 11069441
[TBL] [Abstract][Full Text] [Related]
8. Purification and characterization of two major forms of naloxone reductase from rabbit liver cytosol, new members of aldo-keto reductase superfamily.
Yamano S; Ichinose F; Todaka T; Toki S
Biol Pharm Bull; 1999 Oct; 22(10):1038-46. PubMed ID: 10549852
[TBL] [Abstract][Full Text] [Related]
9. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases.
Rosemond MJ; St John-Williams L; Yamaguchi T; Fujishita T; Walsh JS
Chem Biol Interact; 2004 Mar; 147(2):129-39. PubMed ID: 15013815
[TBL] [Abstract][Full Text] [Related]
10. Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: inversion of stereospecificity with a delta5(10)-3-ketosteroid.
Steckelbroeck S; Jin Y; Oyesanmi B; Kloosterboer HJ; Penning TM
Mol Pharmacol; 2004 Dec; 66(6):1702-11. PubMed ID: 15383625
[TBL] [Abstract][Full Text] [Related]
11. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase.
Burczynski ME; Lin HK; Penning TM
Cancer Res; 1999 Feb; 59(3):607-14. PubMed ID: 9973208
[TBL] [Abstract][Full Text] [Related]
12. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
13. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
Palackal NT; Lee SH; Harvey RG; Blair IA; Penning TM
J Biol Chem; 2002 Jul; 277(27):24799-808. PubMed ID: 11978787
[TBL] [Abstract][Full Text] [Related]
14. The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man.
Malátková P; Havlíková L; Wsól V
Chem Biol Interact; 2014 Sep; 220():241-7. PubMed ID: 25063510
[TBL] [Abstract][Full Text] [Related]
15. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.
Janku F; Johnson LK; Karp DD; Atkins JT; Singleton PA; Moss J
Ann Oncol; 2016 Nov; 27(11):2032-2038. PubMed ID: 27573565
[TBL] [Abstract][Full Text] [Related]
16. High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver.
Breyer-Pfaff U; Nill K
Biochem Pharmacol; 2000 Feb; 59(3):249-60. PubMed ID: 10609553
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolism of fenofibric acid by carbonyl reducing enzymes.
Malátková P; Kanavi M; Nobilis M; Wsól V
Chem Biol Interact; 2016 Oct; 258():153-8. PubMed ID: 27599626
[TBL] [Abstract][Full Text] [Related]
18. New enzymatic assay for the AKR1C enzymes.
Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
[TBL] [Abstract][Full Text] [Related]
19. Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes.
Malátková P; Skarka A; Musilová K; Wsól V
Chem Biol Interact; 2017 Oct; 276():121-126. PubMed ID: 28322780
[TBL] [Abstract][Full Text] [Related]
20. Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases.
Malátková P; Sokolová S; Chocholoušová Havlíková L; Wsól V
Biochem Pharmacol; 2016 Jun; 109():83-90. PubMed ID: 27055738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
